| Literature DB >> 15780734 |
Giuliana Magri1, Mario Clerici, Paola Dall'Ara, Mara Biasin, Maria Caramelli, Cristina Casalone, Maria Laura Giannino, Renato Longhi, Luca Piacentini, Silvia Della Bella, Paola Gazzuola, Piera Anna Martino, Silvia Della Bella, Claudia Pollera, Maria Puricelli, Francesco Servida, Ines Crescio, Adriano Boasso, Wilma Ponti, Giorgio Poli.
Abstract
Effective therapy for prion diseases is currently unavailable. Recently, vaccination was shown to be effective in mouse models of a particular neurodegenerative conditions: Alzheimer's disease (AD). Here, we report that vaccination with synthetic oligopeptides homologous to the hamster (Mesocricetus auratus) prion protein augments survival time in animals infected intraperitoneally with 263K scrapie agent. For each hamster included in the study, prion-specific serum antibodies as well as deposition of pathological prion protein (PrP(res)), glial fibrillary acidic protein (GFAP), and mRNA expression for cytokines (TNF alpha, IL-1beta, IL-10) in brain tissues were evaluated. In immunized animals, increased survival after challenge was associated with a reduction of cerebral lesion, PrP deposition and GFAP expression; in these animals, anti-prion protein peptide antibody levels were increased, and the expression of pro-inflammatory cytokines (TNF alpha and IL-1beta) was reduced. Vaccination could be an effective therapeutic approach to postpone disease onset.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15780734 DOI: 10.1016/j.vaccine.2004.11.067
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641